BioSyent Inc. (CVE:RX) Insider Sells C$1,267,557.28 in Stock

BioSyent Inc. (CVE:RX) insider FAX Capital Corp. sold 112,400 shares of BioSyent stock in a transaction on Monday, December 23rd. The stock was sold at an average price of C$11.28, for a total transaction of C$1,267,557.28.

FAX Capital Corp. also recently made the following trade(s):

• On Friday, November 22nd, FAX Capital Corp. sold 230,800 shares of BioSyent stock. The shares were sold at an average price of C$11.12, for a total transaction of C$2,566,496.00.

BioSyent Stock Performance

CVE:RX opened at C$11.55 on Wednesday. The firm has a market capitalization of C$133.86 million, a PE ratio of 19.25 and a beta of 0.93. The company has a quick ratio of 6.91, a current ratio of 6.13 and a debt-to-equity ratio of 3.19. BioSyent Inc. has a 12-month low of C$8.24 and a 12-month high of C$12.13. The firm has a 50-day moving average price of C$11.32 and a 200 day moving average price of C$10.68.

BioSyent Company Profile

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.